On Aug. 6, the PTO granted a one-year interim extension of the Angiomax patent.
On August 19, APP Pharmaceuticals, which seeks to make a generic brand of bivalirudin, filed a motion to intervene in this matter. The court has yet to hear that motion.
The patent in question is No. 5,196,404, the principal U.S. patent that covers Angiomax.